BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23937277)

  • 1. Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma.
    Gayed BA; Youssef RF; Bagrodia A; Darwish OM; Kapur P; Sagalowsky A; Lotan Y; Margulis V
    BJU Int; 2014 Apr; 113(4):668-73. PubMed ID: 23937277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphovascular invasion in clear cell renal cell carcinoma--association with disease-free and cancer-specific survival.
    Belsante M; Darwish O; Youssef R; Bagrodia A; Kapur P; Sagalowsky AI; Lotan Y; Margulis V
    Urol Oncol; 2014 Jan; 32(1):30.e23-8. PubMed ID: 23428539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of cell cycle and proliferative biomarkers in patients with clear cell renal cell carcinoma.
    Gayed BA; Youssef RF; Bagrodia A; Kapur P; Darwish OM; Krabbe LM; Sagalowsky A; Lotan Y; Margulis V
    J Urol; 2013 Nov; 190(5):1662-7. PubMed ID: 23792148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulation of β-catenin is an independent predictor of oncologic outcomes in patients with clear cell renal cell carcinoma.
    Krabbe LM; Westerman ME; Bagrodia A; Gayed BA; Darwish OM; Haddad AQ; Khalil D; Kapur P; Sagalowsky AI; Lotan Y; Margulis V
    J Urol; 2014 Jun; 191(6):1671-7. PubMed ID: 24291548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma.
    Darwish OM; Kapur P; Youssef RF; Bagrodia A; Belsante M; Alhalabi F; Sagalowsky AI; Lotan Y; Margulis V
    Urology; 2013 Mar; 81(3):581-6. PubMed ID: 23290145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.
    Jorns J; Thiel DD; Lohse CM; Williams A; Arnold ML; Cheville JC; Leibovich BC; Parker AS
    BJU Int; 2012 Oct; 110(7):956-60. PubMed ID: 22300498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma.
    Krabbe LM; Bagrodia A; Lotan Y; Gayed BA; Darwish OM; Youssef RF; John G; Harrow B; Jacobs C; Gaitonde M; Sagalowsky AI; Shariat SF; Kapur P; Margulis V
    J Urol; 2014 Jan; 191(1):28-34. PubMed ID: 23871758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.
    Kruck S; Merseburger AS; Hennenlotter J; Scharpf M; Eyrich C; Amend B; Sievert KD; Stenzl A; Bedke J
    BJU Int; 2012 May; 109(10):1565-70. PubMed ID: 21981759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
    Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
    Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study.
    Ingels A; Hew M; Algaba F; de Boer OJ; van Moorselaar RJ; Horenblas S; Zondervan P; de la Rosette JJ; Pilar Laguna Pes M
    World J Urol; 2017 Jan; 35(1):81-87. PubMed ID: 27207480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma.
    Paly JJ; Hallemeier CL; Biggs PJ; Niemierko A; Roeder F; Martínez-Monge R; Whitson J; Calvo FA; Fastner G; Sedlmayer F; Wong WW; Ellis RJ; Haddock MG; Choo R; Shipley WU; Zietman AL; Efstathiou JA
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):618-23. PubMed ID: 24411190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of a large patient sample to determine p53 and Ki67 expressions in renal cell carcinoma.
    Zheng K; Zhu W; Tan J; Wu W; Yang S; Zhang J
    J BUON; 2014; 19(2):512-6. PubMed ID: 24965414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
    Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
    BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers.
    Minervini A; Di Cristofano C; Gacci M; Serni S; Menicagli M; Lanciotti M; Salinitri G; Rocca CD; Lapini A; Nesi G; Bevilacqua G; Minervini R; Carini M
    J Urol; 2008 Oct; 180(4):1284-9. PubMed ID: 18707725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases.
    Bertini R; Roscigno M; Freschi M; Strada E; Petralia G; Pasta A; Matloob R; Sozzi F; Da Pozzo L; Colombo R; Guazzoni G; Doglioni C; Montorsi F; Rigatti P
    J Urol; 2009 May; 181(5):2027-32. PubMed ID: 19286201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to recurrence after nephrectomy as a predictor of cancer-specific survival in localized clear-cell renal cell carcinoma.
    Rodriguez-Covarrubias F; Gomez-Alvarado MO; Sotomayor M; Castillejos-Molina R; Mendez-Probst CE; Gabilondo F; Feria-Bernal G
    Urol Int; 2011; 86(1):47-52. PubMed ID: 20814191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
    Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
    BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of clinical variables on predicting disease-free survival of patients with surgically resected renal cell carcinoma.
    Brookman-Amissah S; Kendel F; Spivak I; Pflanz S; Roigas J; Klotz T; May M
    BJU Int; 2009 May; 103(10):1375-80. PubMed ID: 19040527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.